In: Main
25 Jun 2010Table 5 lists all treatment-related clinical adverse events that occurred in 3% or more of the Hepsera™-treated patients compared with those receiving placebo. Increased asthenia, headache, and abdominal pain are the most frequently reported adverse events, followed by nausea and flatulence. Two other less commonly reported side effects are diarrhea and dyspepsia.
In: Main
24 Jun 2010From a 10-mg single dose of Hep-sera™, the approximate bioavailability of adefovir is 59%. After oral administration of a 10-mg single dose of Hepsera™ to patients with chronic hepatitis B, the peak adefovir plasma concentration has been 18.4 + 6.26 ng/ml, occurring between 0.58 and 4.00 hours after a dose. The adefovir area under the [...]
In: Main
23 Jun 2010INTRODUCTION
The leading cause of cirrhosis and hepatocellular carcinoma around the world is chronic hepatitis B virus (HBV) infection. Approximately 10% of patients who carry the human immunodeficiency virus (HIV) in the U.S. are co-infected with HBV and face decreased survival rates. Worldwide, 400 million people are chronically infected with hepatitis B.
In: Main
20 Jun 2010Don’t assume for a second that Republican control of the House, Senate, and White House ensures passage of the Bush Medicare drug benefit, or any other benefit for that matter, in 2003. Although Republican leaders on Capitol Hill gave President Bush’s hazy, early March drug proposal polite applause, you didn’t need special, Pentagon-issue night-vision goggles [...]
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.